

patent the Commission determined to review (1) the ID's finding that a combination of prior art references Doppelt, Jacobs, and Gilbert fail to render the asserted claims obvious; and (2) the ID's finding that a combination of prior art references Matsuoka, Doppelt, and Eckel fail to render the asserted claims obvious. For the '336 patent the Commission determined to review (1) the ID's finding that claim 34 recites ineligible patent subject matter under 35 U.S.C. 101; and (2) the ID's finding that Pruessel, either alone or in combination with Koestler, fails to render claim 34 obvious. The Commission requested the parties to brief certain issues. *Id.* On January 5, 2018, the parties filed submissions to the Commission's question and on remedy, the public interest, and bonding. *See* Complainant's Response to Request for Written Submissions Regarding Issues Under Review; Respondents' Response to Request for Written Submissions Regarding Issues Under Review. On January 12, 2018, the parties filed reply submissions. *See* Complainant's Reply to Respondents' Submission Addressing the Commission's December 22, 2017 Notice; Respondents' Reply to Complainant's Submission Regarding Issues Under Review.

Having examined the record of this investigation, including the final ID, and the parties' submissions, for the '319 patent the Commission has determined to (1) affirm the ALJ's finding that a combination of prior art references Doppelt, Jacobs, and Gilbert fail to render the asserted claims obvious and (2) affirm the ALJ's finding that a combination of prior art references Matsuoka, Doppelt, and Eckel fail to render the asserted claims obvious, but reverse the ALJ's finding that Eckel is analogous art. For the '336 patent the Commission has determined to (1) affirm the ALJ's finding that Pruessel, either alone or in combination with Koestler, fails to render claim 34 obvious and (2) take no position on the ALJ's finding that claim 34 recites ineligible patent subject matter under 35 U.S.C. 101. The Commission adopts the ID's findings to the extent they are not inconsistent with the Commission opinion issued herewith.

Having found a violation of section 337 in this investigation, the Commission has determined that the appropriate form of relief is: (1) A limited exclusion order prohibiting the unlicensed entry of access control systems and components thereof that infringe one or more of claims 1–4, 7–12, 15, and 16 of the '319 patent that are manufactured by, or on behalf of, or are

imported by or on behalf of Respondents or any of their affiliated companies, parents, subsidiaries, agents, or other related business entities, or their successors or assigns, are excluded from entry for consumption into the United States, entry for consumption from a foreign-trade zone, or withdrawal from a warehouse for consumption, for the remaining term of the '319 patent except under license of the patent owner or as provided by law; and (2) cease and desist orders prohibiting TTi HK, TTi NA, One World, and OWT from conducting any of the following activities in the United States: Importing, selling, marketing, advertising, distributing, transferring (except for exportation), and soliciting U.S. agents or distributors for, access control systems and components thereof covered by one or more of claims 1–4, 7–12, 15, and 16 of the '319 patent.

The Commission has also determined that the public interest factors enumerated in section 337(d) and (f) (19 U.S.C. 1337(d) and (f)) do not preclude issuance of the limited exclusion order or cease and desist orders. Finally, the Commission has determined that a bond in the amount of zero is required to permit temporary importation during the period of Presidential review (19 U.S.C. 1337(j)) of access control system and components thereof that are subject to the remedial orders. The Commission's orders and opinion were delivered to the President and to the United States Trade Representative on the day of their issuance.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: March 23, 2018.

Katherine Hiner,

Supervisory Attorney.

[FR Doc. 2018–06293 Filed 3–28–18; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, Inc.

ACTION: Notice; Correction.

SUMMARY: The Drug Enforcement Administration (DEA) published a

document in the **Federal Register** on February 6, 2018, concerning a notice of application that inadvertently did not include the controlled substance levorphanol (9220).

Correction

In the **Federal Register** on February 6, 2018, in FR Doc No: 2018–02343 (83 FR 5274), correct the table to include the following basic class of controlled substance:

Controlled substance	Drug code	Schedule
Levorphanol	9220	II

Dated: March 15, 2018.

Susan A. Gibson,

Deputy Assistant Administrator.

[FR Doc. 2018–06327 Filed 3–28–18; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Application: Fisher Clinical Services, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 30, 2018. Such persons may also file a written request for a hearing on the application on or before April 30, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION:

The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with